The Role for ink4a in Melanoma Pathogenesis

[1]  F. Kaye,et al.  Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. , 1994, Oncogene.

[2]  Nobuyuki Shishido,et al.  Mice Lacking p27 Kip1 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors , 1996, Cell.

[3]  A. Balmain,et al.  Hyperpigmentation and melanocytic hyperplasia in transgenic mice expressing the human T24 HA‐ras gene regulated by a mouse tyrosinase promoter , 1995, Molecular carcinogenesis.

[4]  K. Isobe,et al.  Aberrant melanogenesis and melanocytic tumour development in transgenic mice that carry a metallothionein/ret fusion gene. , 1991, The EMBO journal.

[5]  R. Weinberg,et al.  Effects of an Rb mutation in the mouse , 1992, Nature.

[6]  A. Kopf,et al.  Lifetime risk for development of skin cancer in the U.S. population: current estimate is now 1 in 5. , 1996, Journal of the American Academy of Dermatology.

[7]  L. J. Veer,et al.  N-ras mutations in human cutaneous melanoma from sun-exposed body sites , 1989, Molecular and cellular biology.

[8]  P. Heinzel,et al.  Mutations and polymorphisms in the p53, p21 and p16 genes in oral carcinomas of Indian betel quid chewers , 1996, International journal of cancer.

[9]  S. Jhanwar,et al.  Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. , 1992, Oncogene.

[10]  K. Kinzler,et al.  Deletion of p16 and p15 genes in brain tumors. , 1994, Cancer research.

[11]  S. Suster,et al.  Induction of different morphologic features of malignant melanoma and pigmented lesions after transformation of murine melanocytes with bFGF-cDNA and H-ras, myc, neu, and E1a oncogenes. , 1991, The American journal of pathology.

[12]  S. Tavtigian,et al.  Complex structure and regulation of the P16 (MTS1) locus. , 1995, Cancer research.

[13]  H. Sasano,et al.  In situ hybridization and immunohistochemistry of p53 tumor suppressor gene in human esophageal carcinoma. , 1992, The American journal of pathology.

[14]  W. Gerald,et al.  Analysis of p21WAF1/CIP1 in primary bladder tumors. , 1998, Oncology research.

[15]  P. O'Connor,et al.  A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma. , 1995, Cancer research.

[16]  E. Newcomb,et al.  Alterations of multiple tumor suppressor genes (p53 (17p13), p16INK4 (9p21), and DBM (13q14)) in B‐CELL chronic lymphocytic leukemia , 1995, Molecular carcinogenesis.

[17]  G. Hannon,et al.  Deletion of the p16 and p15 genes in human bladder tumors. , 1995, Journal of the National Cancer Institute.

[18]  K. Manova-Todorova,et al.  Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27 Kip1 , 1996, Cell.

[19]  M. Skolnick,et al.  Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus , 1994, Nature Genetics.

[20]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[21]  C. Cordon-Cardo,et al.  Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. , 1994, Cancer research.

[22]  A. Monaghan,et al.  A cell‐specific enhancer far upstream of the mouse tyrosinase gene confers high level and copy number‐related expression in transgenic mice. , 1994, The EMBO journal.

[23]  L. Chin,et al.  Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.

[24]  L. Sandkuijl,et al.  Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds , 1995, Nature Genetics.

[25]  C. Cordon-Cardo.  Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. , 1995, The American journal of pathology.

[26]  T. Hunter,et al.  Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.

[27]  M. Schartl,et al.  The Xmrk receptor tyrosine kinase is activated in Xiphophorus malignant melanoma. , 1992, The EMBO journal.

[28]  A. Kamb,et al.  Cell-cycle regulators and cancer. , 1995, Trends in genetics : TIG.

[29]  D. Carson,et al.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.

[30]  F. Zindy,et al.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest , 1995, Cell.

[31]  R. Wilson,et al.  Induction of tumorigenicity and lack of in vitro growth requirement for 12-O-tetradecanoylphorbol-13-acetate by transfection of murine melanocytes with v-Ha-ras. , 1989, Cancer research.

[32]  G. Hannon,et al.  Cloning and characterization of murine p16INK4a and p15INK4b genes. , 1995, Oncogene.

[33]  H. Koeffler,et al.  p27/Kip1 mutation found in breast cancer. , 1996, Cancer research.

[34]  W. Gerald,et al.  Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors. , 1996, Cancer research.

[35]  Stephen J. Elledge,et al.  Mice Lacking p21 CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control , 1995, Cell.

[36]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[37]  A. Gown,et al.  p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. , 1995, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[38]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[39]  G. Hannon,et al.  Cloning and characterization of murine p16(INK4a) and p15(INK4b) genes , 1995 .

[40]  R. Sharp,et al.  Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Van Dyke Ta,et al.  Analysis of viral-host protein interactions and tumorigenesis in transgenic mice. , 1994 .

[42]  H. Höfler,et al.  Ras gene mutations: a rare event in nonmetastatic primary malignant melanoma. , 1995, The Journal of investigative dermatology.

[43]  H. Dosaka-akita,et al.  Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. , 1996, Cancer research.

[44]  D. Grignon,et al.  Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. , 1995, Oncogene.

[45]  N. Hayward,et al.  Mutations and defective expression of the WAF1 p21 tumour‐suppressor gene in malignant melanomas , 1995, Melanoma research.

[46]  K. Isselbacher,et al.  Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[47]  W. Clark,et al.  Germline p16 mutations in familial melanoma , 1994, Nature Genetics.

[48]  James M. Roberts,et al.  A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27 Kip1 -Deficient Mice , 1996, Cell.

[49]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[50]  S. Ogawa,et al.  Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies. , 1996, Blood.

[51]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[52]  M. Bulyk,et al.  Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. , 1996, Cancer research.

[53]  Gregory J. Hannon,et al.  pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest , 1994, Nature.

[54]  F. Real,et al.  Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. , 1988, The Journal of investigative dermatology.

[55]  S. Elledge,et al.  A question of balance: the role of cyclin-kinase inhibitors in development and tumorigenesis. , 1996, Trends in cell biology.

[56]  C. Cordon-Cardo,et al.  Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. , 1989, Oncogene.

[57]  M. Hollstein,et al.  Clinical implications of the p53 tumor-suppressor gene. , 1993, The New England journal of medicine.

[58]  H. Koeffler,et al.  Role of the cyclin-dependent kinase inhibitors in the development of cancer. , 1995, Blood.

[59]  C. Poremba,et al.  Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression. , 1995, Oncology research.

[60]  J. Hoeffler,et al.  Ras mutations in human melanoma: a marker of malignant progression. , 1994, The Journal of investigative dermatology.

[61]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.